VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

por Kuiper, J L, Lind, J S W, Groen, H J M, Roder, J, Grigorieva, J, Roder, H, Dingemans, A M C, Smit, E F
Publicado 2012

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

por Kuiper, J L, Hashemi, S M S, Thunnissen, E, Snijders, P J F, Grünberg, K, Bloemena, E, Sie, D, Postmus, P E, Heideman, D A M, Smit, E F
Publicado 2016

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression

por van der Wekken, A. J., Kuiper, J. L., Saber, A., Terpstra, M. M., Wei, J., Hiltermann, T. J. N., Thunnissen, E., Heideman, D. A. M., Timens, W., Schuuring, E., Kok, K., Smit, E. F., van den Berg, A., Groen, H. J. M.
Publicado 2017